Abstract
Prostate cancer (PCa) is the most common internal malignancy and the third most frequent cause of cancer death in men. It is estimated that in each week of 2009 over 490 Canadian men were diagnosed with PCa, and 85 will have died from the disease. The introduction of PSA (prostate-specific antigen) screening tests has contributed in part, to men being diagnosed and treated at an early stage. Chemoprevention is a strategy whereby patients are administered drugs, vitamins, or other agents to prevent/reduce the risk of cancer progression and/ or delay the development of its recurrence thereby decreasing patient morbidity and mortality. PCa has a long latency period, thereby offering plenty of opportunity to intervene through the implementation of chemopreventive therapies. A large body of epidemiologic evidence, together with published data from in vivo and in vitro studies, strongly supports relationships between dietary constituents and the risk of prostate cancer. This article aims to review the diverse aspects of chemoprevention including the benefit of both macro- and micronutrients that have been implicated in prostate cancer prevention. In addition we discuss perspectives on the putative mechanisms of selected chemopreventive agents and highlight several clinical studies using specific chemopreventive interventions.
Keywords: Prostate cancer, diet, micronutrients, flavonoids, in vivo, clinical trials.
Current Cancer Therapy Reviews
Title:Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Volume: 6 Issue: 4
Author(s): Natalie A. Venier, Laurence H. Klotz, Neil E. Fleshner and Vasundara Venkateswaran
Affiliation:
Keywords: Prostate cancer, diet, micronutrients, flavonoids, in vivo, clinical trials.
Abstract: Prostate cancer (PCa) is the most common internal malignancy and the third most frequent cause of cancer death in men. It is estimated that in each week of 2009 over 490 Canadian men were diagnosed with PCa, and 85 will have died from the disease. The introduction of PSA (prostate-specific antigen) screening tests has contributed in part, to men being diagnosed and treated at an early stage. Chemoprevention is a strategy whereby patients are administered drugs, vitamins, or other agents to prevent/reduce the risk of cancer progression and/ or delay the development of its recurrence thereby decreasing patient morbidity and mortality. PCa has a long latency period, thereby offering plenty of opportunity to intervene through the implementation of chemopreventive therapies. A large body of epidemiologic evidence, together with published data from in vivo and in vitro studies, strongly supports relationships between dietary constituents and the risk of prostate cancer. This article aims to review the diverse aspects of chemoprevention including the benefit of both macro- and micronutrients that have been implicated in prostate cancer prevention. In addition we discuss perspectives on the putative mechanisms of selected chemopreventive agents and highlight several clinical studies using specific chemopreventive interventions.
Export Options
About this article
Cite this article as:
A. Venier Natalie, H. Klotz Laurence, E. Fleshner Neil and Venkateswaran Vasundara, Dietary Agents for Prostate Cancer Chemoprevention: An Overview, Current Cancer Therapy Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339410793358093
DOI https://dx.doi.org/10.2174/157339410793358093 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Participation of the Cannabinoid System in the Regulation of Emotional- Like Behaviour
Current Pharmaceutical Design Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets Integrins as A New Target for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry From the RB Tumor Suppressor to MCR Peptides
Protein & Peptide Letters Ovarian Aging: Melatonin Regulation of the Cytometric and Endocrine Evolutive Pattern
Current Aging Science Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry Automated One-pot Radiosynthesis of [11C]S-adenosyl Methionine
Current Radiopharmaceuticals Fat Digestion and its Role in Appetite Regulation and Energy Balance -The Importance of Enterostatin and Tetrahydrolipstatin
Current Medicinal Chemistry - Central Nervous System Agents Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Current Signal Transduction Therapy Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience MUC1 is a Promising Therapeutic Target for Prostate Cancer Therapy
Current Cancer Drug Targets Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Achieving Detumescence of Ischemic Priapism with Intra-Cavernosal Injection of entanyl: An Unexpected Outcome of Miscommunication Error
Current Drug Safety NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry